Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Indirect evidence to demonstrate that slow pot-prandial gastric emptying should not result in substantial gastric retention 12 hours after the last meal. (A) Six-hour gastric emptying tests (13C- octanoate breath for labeling solid meal components) analyzed using Wagner-Nelson equations were performed in 47 T2D subjects at baseline (black curves, with dotted lines indicating ± 95% confidence intervals). Results from subjects with substantially decelerated gastric emptying (at baseline or 10 weeks after initiating treatment with lixisenatide [20 µg/d] or liraglutide [1.8 mg/d]) are also shown. Gastric emptying curves between 6.5 and 12 hours after meal intake were interpolated assuming an exponential decay (from an initial plateau of 100%) based on the measurements during the initial 6 hours. Even those with slow gastric emptying achieved a gastric content near 0% by 12 hours, which would be a typical interval between a last meal (eg, dinner at 7 Pm) and an early procedure (endoscopy or general anesthesia) in the morning of the following day. Data used for display and modeling are from Quast et al (40). (B) Residual gastric content from food ingested on the previous day (or earlier) as visualized in the gastric antrum by upper gastrointestinal tract endoscopy (courtesy Diabetes Center Bad Lauterberg). Abbreviations: T2D, type 2 diabetes.](https://figures.cochat.ai/paper-figures/7d35bedb7ee940febd956b76a9173f53/clinical-consequences-of-delayed-gastric-emptying-with-glp-1-receptor-agonists-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of its GLP-1 component also delays gastric emptying, blunting postprandial glucose excursions and contributing to steadier overall glucose profiles [69].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second is pharmacokinetic: GLP-1 agonists slow gastric emptying and so alter the absorption rate of oral drugs [47,120], while berberine inhibits enzymes and transporters at the same intestinal interface, so the two perturb one process from different directions [46,47].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [120]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This difference is believed to result from tachyphylaxis associated with prolonged GLP-1 RA use, leading to attenuation of the gastric emptying–delaying effect, which becomes more evident with long-acting formulations [32,33].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Based on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and…”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“Monnier at al reported that PPG is a dominant contributor to overall glycemia in T2D (as assessed by measurement of hemoglobin A 1c ), especially in well-controlled diabetes [calculated to contribute approximately 70% when hemoglobin A 1c is ≤ 7.3% (3)].”
InfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“…on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and obesity.”
Identifying and Avoiding Bias in Research
Pannucci, C. J., & Wilkins, E. G. (2010) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181de24bc · Cited by 1,079 · cited 1×
“…to see what one expects to see (eg, in studies where the examiner was not blinded to the patients ’ health status or treatment); publication bias describes the fact that results not compatible with the original hypothesis have a lesser chance to be submitted or accepted for publication (116).”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“…refer to Supplementary Table S1 for more data on the effect of GLP-1 receptor agonists on gastric emptying in subjects with type 2 diabetes and obesity. imprecise measurement techniques (31) like the paracetamol (acetaminophen) absorption technique, which continues to be used extensively (32-34).”
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 1×
“This dose-dependent slowing of gastric emptying represents a major mechanism contributing to PPG lowering by exogenous GLP-1 and, in healthy humans, “ outweighs ” its insulinotropic effects such that postprandial insulin secretory responses are suppressed rather than stimulated (15, 16).”
Self-citationVantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815 · cited 1×
“…phase 3 of this complex, which is composed of pressure waves often originating in the stomach and propagated segment by segment toward the duodenum and jejunum (108), which is thought to clear the remnants of the preceding meal including indigestible gastric content from the stomach (108, 109).”
Clinical Significance of Pulmonary Aspiration during the Perioperative Period
Warner, M. A., Warner, M. E., & Weber, J. G. (1993) · Anesthesiology · doi:10.1097/00000542-199301000-00010 · Cited by 808 · cited 1×
“This is a rare complication of general anesthesia, with an incidence of approximately 1 per 3000 elective surgery cases, resulting in death in approximately 1 per 70 000 cases (106).”
Research works printed but not linked: 3
- Schick RR, Zimmermann JP, vorm Walde T, Schusdziarra V, Classen M. Glucagon-like peptide (GLP)-1(7-36)-amide: a central suppressor of food intake in rats (abstract). Gastroenterol. 1992; 102: A756.
- Code CF, Schlegel JF. The gastrointestinal interdigestive housekeeper: motor correlates of the interdigestive myoelectric complex of the dog. In: Daniel EE, Gilbert JAL, Schofield B, Schnitka TK, Scott G, eds. Proceedings of the Fourth International Symposium on Gastrointestinal Motility. Vancouver Mitchell Press Ltd.; 1974: 631‐ 634.
- American Gastroenterological Association. AGA does not endorse all patients stopping popular diabetes and weight loss drugs prior to endoscopy. 2023. Accessed May 28, 2024. https://gastro.org/press-releases/continue-glp1-drugs-before-endoscopy/
Cited by
Items 101–156 of 156
THE DARK SIDE OF GLP-1 ANALOGS: ADVERSE EFFECTS, LIMITATIONS, AND SAFETY CONCERNS
Dudzińska, K., Kaftan, A., Plenikowski, J., Kahsin, A., Kacprzak, S., Greluk, A., Żuk, J., Ciszewski, W., Jurewicz, A., & Plenikowska, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5655
Dost, B., Turunç, E., Narayanan, M. K., Koneti, K. K., Bugada, D., Karapınar, Y. E., & CASSAI, A. D. (2026) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_91_26 · Cited by 1
Baker, F. A., Melhem, M., Kalnizki, O., Khader, M., Dardik, M., Tatour, M., & Hazzan, R. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002360
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Abegaz, T. M., Frietze, G. A., & Das, A. B. (2026) · AI in Medicine · doi:10.3390/aimed1030019
“In this context, the pharmacologic effects of GLP-1 RAs—particularly their known action of slowing gastric emptying—may further exacerbate pre-existing motility disturbances, resulting in a higher burden of gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort [30,31].”
An Overlooked Impact of GLP-1 Receptor Agonists on Enteric Coated Medications
Atef, E., & Elkeeb, R. (2026) · Open Journal of Pharmacology and Pharmacotherapeutics · doi:10.17352/ojpp.000030
Lai, H., Sun, T., & Yu, X. F. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-05161-1
“In particular, glucagon-like peptide-1 receptor agonists have attracted increasing attention because of their potential to delay gastric emptying and alter gastrointestinal transit [59, 60].”
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Targeting gastrointestinaI function beyond GLP-1 to control appetite
Tack, J. F., Scarpellini, E., Sosoranga, E. R., Matheussen, H., von Mühlenbrock, C., Carbone, F., & den Houte, K. V. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102129
Implications of Medications in Gastrointestinal Motility
Peixoto, A., Araújo, F. D., Maciel, P., Frias, J., & Câmara, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27658-3.00025-1
An Updated Review of Glucagon-Like Peptide-1 Receptor Agonists
Coleman, J. R., Levine, A., & Weigel, W. (2026) · Advances in Anesthesia · doi:10.1016/j.aan.2026.04.001
Bigge, S., & Bigge, B. (2026) · International Journal of Research in Dermatology · doi:10.18203/issn.2455-4529.intjresdermatol20262851
Obesity and Upper Aerodigestive Dysfunction
Ali, S., Jamal, N., & BRACKEN, D. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.07.002
Ogawa, O. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70426
Torrie, A. M., Tindal, S., Wilhelm, Z., Kommu, K., Harris, A. D., Slobogean, G. P., O’Toole, R. V., & O’Hara, N. N. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-026-04932-6
Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine
Mataraarachchi, N. E., Dellinger, O. D., & Babakhanians, A. (2026) · Cureus · doi:10.7759/cureus.115380
“A pharmacologic consequence of GLP-1 receptor agonism is delayed gastric emptying, mediated through GLP-1-and GIP-receptor-dependent inhibition of antral motility and pyloric contraction [3,4].”
Kaczynski, M., Zureikat, R. M., Kaczynski, M. R., Sitarz, R., & Karakuła‐Juchnowicz, H. (2026) · Biomedicines · doi:10.3390/biomedicines14091957
“Jalleh et al. described consequences of delayed gastric emptying with GLP-1RAs and tirzepatide, including retained gastric contents at endoscopy, aspiration risk, and altered drug absorption [105].”
Kavsara, H. K. (2026) · Journal of Medical Topics and Updates · doi:10.58651/jomtu.1980569
Choudhary, A. K., & Sahu, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10780569/v1
Nascimento, G. L. M., da Silva, B. W. V., de Souza, F. V., Corrêa, S. B. P., Machado, V. D. F., SILVA, I. R. D., Lopatiuk, C. E., SILVA, T. O. D., Andrade, A. N. D., & Castro, M. A. D. A. (2026) · Aracê. · doi:10.56238/arev8n8-136
Comparison of Ultrasound and Scintigraphy in Gastric Emptying: A Comprehensive Review
Lein, E., Jones, K. L., & Gilja, O. H. (2026) · Diagnostics · doi:10.3390/diagnostics16172816
Self-citationModern pharmacological therapies in nephrology: Progress, promises, and the forgotten role of diet
Borges, N. A., Cardozo, L., Leal, V. D. O., da Silva, L. D. S. F. V., Wesson, D. E., Fouque, D. P., & Mafra, D. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106781
O’Brien, H., Byrne, A. J., Franciosi, A. N., & Butler, M. W. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00380-z
“…adverse events, such as nausea, reflux, diarrhea, and delayed gastric emptying, are the most common reason for discontinuing GLP-1RA therapy and warrant specific counseling in patients with asthma, particularly in those in whom reflux already significantly contributes to symptom burden [99, 100].”
Viana, D. P. D. C., Invitti, A. L., Jacobsen, L., & Schor, E. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109116
Safety Considerations for Hospitalized Children and Adolescents With Obesity
Gilley, S. P., Nell, T., Wang, A. A., Diab, L., Cooley, M., Ross, E. L., Moore, J. M., Eneli, I., & Haemer, M. A. (2026) · Hospital Pediatrics · doi:10.1542/hpeds.2026-009253
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
“17 This author does not recommend using anti ‐ emetics or erythromycin in patients with GLP ‐ 1 RA ‐ induced nausea.”
Seo, J., Choi, S., Kim, N., Kim, H., & Lim, H.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846164
Djebbara-Bozo, N., Yilmaz, M., Saritas, S., Birk‐Sørensen, L., & Krag, A. E. (2026) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2026.09.040 · Cited by 2
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Mahmood, T., Myrtziou, I., & Kanakis, I. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02089-x
“Net benefit should therefore be considered as a balance among glycaemic efficacy, hypo - glycaemia, weight, treatment burden, and tolerability rather than as unconditional superiority [45 , 46 ].”
Vlaeminck, N., & Saldien, V. (2026) · British Journal of Anaesthesia · doi:10.1016/j.bja.2026.07.075
Chung, J. (2026) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2026.34.e13
“Continuous GLP-1 receptor stimulation produces tachyphylaxis of the emptying effect whereas intermittent stimulation does not, so prolongation of emptying half-time declines over time for long-acting but not short-acting agents [13].”
Amoyel, M., Lebtahi, R., Poghosyan, T., Gall, M. L., & Soliman, H. (2026) · Comprehensive physiology · doi:10.1002/cph4.70275
Lithium toxicity following initiation of tirzepatide in a patient with bipolar I disorder
Patel, J. B., Islam, S., Sharma, R., Alhunayan, T., Vora, V., Bach, G., Panchal, K., Emara, A. T., Rodriguez, L., Suthar, H. J., et al. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20263555
Ahmad, A. E., Yamani, N. T., Alaqaili, A. F., Aldawas, S. S., Alotaib, N. Q., & Eldawlatly, A. A. (2026) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_177_26
“[3] This risk is increased by factors such as a full stomach, impaired airway protection reflexes, and decreased levels of consciousness.”
Faggiano, A., Argentiero, A., Borghesani, G., Haxhi, J., Camastra, S., Cinieri, S., Cortellini, A., Re, M. D., Gallo, M., Natalicchio, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70231
Briere, D. A., Leohr, J. K., Linnebjerg, H., Muppidi, A., Antonellis, M. P., Antonellis, P. J., Suter, T. M., LaBell, E. S., Lopes, D., Dogra, M., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102452
“The magnitude of gastric emptying effects observed with nisotirostide is comparable to that reported for long-acting GLP-1 RAs after multiple doses [33].”
Chaturvedi, R., Singh, K., Chakole, R., Yadav, B. K., Dhameliya, J., & Joshi, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969433 · Cited by 2
Sibal, R., Balamurugan, G., Aradaib, M., Graham, Y. N. H., & Mahawar, K. K. (2026) · Medicina · doi:10.3390/medicina62101916
“…occupancy, delayed gastric emptying, neurohormonal effects [21,22] Appetite suppression, delayed gastric emptying, central satiety signalling [45,46] Delivery Endoscopic placement; temporary (~6 months) Subcutaneous injection; weekly or daily Total body weight loss ~10–15% TBWL at 6 months…”
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
“Gastrointestinal adverse events cannot be attributed solely to delayed gastric emptying, and a direct quantitative relationship between gastric-emptying delay, nausea, and the plateau in weight loss has not been established [ 37].”
Eliseeva, E. M., Druzhinina, A. A., & Chistokhina, A. A. (2026) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2026-14-3-249-262
Palm, U., Backmund, M., & Himmerich, H. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1880796
“Generally, GLP-1 RAs anti-obesity medications do not only elicit gastrointestinal effects and side effects such as delayed stomach emptying (Jalleh et al., 2024) and hormonal changes, e.g., in insulin, glucagon, ghrelin, cortisol and vasopressin (Diz-Chaves et al., 2020) but also suppress appetite…”
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
“Clinically, its dual GIP/GLP-1 receptor agonism synergistically delays gastric emptying, reduces ghrelin-stimulated acid secretion, and stabilises postprandial glucose absorption, collectively suppressing caloric intake by 20–30% versus placebo [146].”
Asiri, A., DANIELS, R., Najim, A., Razak, H. R. A., & Mokbel, K. (2026) · Diabetology · doi:10.3390/diabetology7100200
焦, 梦. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103405
Zhou, L., Liang, W., Liu, Y., Wu, Z., 张文婷, Li, J., Feng, J., Shi, L., & Li, M. (2026) · Research Square · doi:10.21203/rs.3.rs-11093494/v1
Gastrointestinal Symptom Events and Motility Alterations Associated With GLP ‐1 Receptor Agonists
Cisneros, J. Z., Lupianez‐Merly, C., Dilmaghani, S., Lennon, R. J., Then, S., Fiero, P., Blundo, R., Farrugia, G., Camilleri, M., & Grover, M. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70458
Yan, Y., Xu, M., Lu, S., Liang, Z., & Shen, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-11029518/v1
Toward Precision Prescribing of GLP-1 Receptor Agonists for Glucose Lowering
Umapathysivam, M. M. (2026) · Diabetes Care · doi:10.2337/dci26-0115
Self-citationLiu, F., Xu, Z., Wang, W., Gao, J., Changgeng, F. U., & Liu, P. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1996288
“Nevertheless, they provide more stable control of fasting and whole-day blood glucose levels (Jalleh et al., 2024).”
Perioperative management of GLP-1 receptor agonists: adult evidence and future directions
Varga, G. J., Lazzareschi, D. V., & Sadhasivam, S. (2026) · Frontiers in Anesthesiology · doi:10.3389/fanes.2026.1991524
Roslin, K., Andrews, R., Baella-Olivieri, B., & Roslin, M. S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15218265
Kumbhare, S. V., Pedroso, I., Sinha, R., & Almonacid, D. E. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2026.2016564
Serebrova, S. Y., Gorodetskaya, G. I., Lazareva, N. B., Demchenkova, E. Y., Еременко, Н. Н., Bogdanova, N. G., & Zhuravleva, M. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-425
Wisdom, E. M., Goldlist, K., Lieber, S. B., Marwell, J. G., Neukam, S., Johnston, E. A., Batsis, J. A., Eckstrom, E., & Wagle, K. C. (2026) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70769 · Cited by 1
Metadata
- Authors
- Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- St. Josef-Hospital (DE)
- The University of Adelaide (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-17
- Volume
- 110
- Issue
- 1
- Pages
- 1-15
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC11651700
- OpenAlex
- W4403479516
- Cited by
- 157
- References
- 120
- Citations by year
- 2026: 110 · 2025: 45 · 2024: 2
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Funders
- Mary Overton postdoctoral fellowship
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- GLP-1 receptor agonists, tirzepatide, delayed gastric emptying, pulmonary aspiration, upper gastrointestinal endoscopy, periprocedural management, type 2 diabetes, obesity, tachyphylaxis, prokinetic agents, erythromycin, point-of-care ultrasound, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Emptying, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.